Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: A systematic review and meta-analysis

A number of studies have reported hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) after treatment with immune checkpoint inhibitor (ICI). This study aimed to summarize the incidence and survival outcome of HPD in NSCLC and identify the clinicopathological features associated with HPD based on available eligible studies. | Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor A systematic review and meta-analysis

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
14    1    0    28-10-2020